Core Viewpoint - The approval of the drug "Gelong Bromide" by the National Medical Products Administration marks a significant milestone for the company, indicating potential growth in the pharmaceutical market [1] Company Summary - The company, Jiuzhoutong, announced that its subsidiary, Beijing Jingfeng Pharmaceutical (Shandong) Co., Ltd., received the approval for the listing application of Gelong Bromide on October 16, 2025 [1] - Gelong Bromide is a quaternary ammonium anticholinergic drug that selectively acts on the digestive tract, inhibiting gastric secretion and adjusting gastrointestinal motility [1] Product Summary - Gelong Bromide can be used for treating gastric and duodenal ulcers, chronic gastritis, and as a maintenance treatment for chronic obstructive pulmonary disease (COPD) in adults, including chronic bronchitis and emphysema [1] - The drug works by specifically binding to and inhibiting the M3 acetylcholine receptors distributed in bronchial smooth muscle, leading to airway dilation [1]

Core Viewpoint - The approval of the drug "Gelong Bromide" by the National Medical Products Administration marks a significant milestone for the company, enhancing its product portfolio in the pharmaceutical sector [1] Company Summary - The company, through its subsidiary Beijing Jingfeng Pharmaceutical (Shandong) Co., Ltd., received the approval for the marketing application of Gelong Bromide on October 16, 2025 [1] - Gelong Bromide is a quaternary ammonium anticholinergic drug that selectively acts on the gastrointestinal tract, inhibiting gastric secretion and adjusting gastrointestinal motility [1] Product Details - Gelong Bromide can be used for treating gastric and duodenal ulcers, chronic gastritis, and as a maintenance treatment for chronic obstructive pulmonary disease (COPD) in adults, including chronic bronchitis and emphysema [1] - The drug specifically binds to and inhibits the M3 acetylcholine receptors in bronchial smooth muscle, leading to airway dilation [1]

Core Viewpoint - The approval of the listing application for Glycopyrrolate by the National Medical Products Administration is expected to positively impact the future development of the company's pharmaceutical industrial business and enhance its competitiveness in the active pharmaceutical ingredient market [1] Group 1: Company Developments - The company's subsidiary, Beijing Jingfeng Pharmaceutical (Shandong) Co., Ltd., received the approval notice for the listing application of Glycopyrrolate on October 16, 2025 [1] - Glycopyrrolate is a quaternary ammonium anticholinergic drug used for treating gastric and duodenal ulcers, chronic gastritis, and for maintaining bronchial dilation in adult patients with chronic obstructive pulmonary disease [1] - The approval will enrich the company's product line and strengthen its market position in the active pharmaceutical ingredient sector [1]

Core Viewpoint - The announcement details the investment activities of Jiuzhoutong Pharmaceutical Group Co., Ltd. regarding entrusted financial management for the third quarter of 2025, highlighting the company's strategy to utilize idle funds for investment while ensuring operational liquidity and safety [2][4][12]. Investment Overview - The maximum balance of entrusted financial management for the third quarter of 2025 was 1.3 billion RMB, with a balance of 0 RMB at the end of the quarter [5][12]. - The company plans to use up to 4 billion RMB of idle funds for purchasing safe and liquid financial products, with individual investment periods not exceeding 12 months [2][8]. Investment Purpose - The purpose of the investment is to enhance the efficiency of fund utilization and generate investment returns without affecting the company's normal operational funding needs [4][12]. Funding Source - The funds for the entrusted financial management products in the third quarter of 2025 were sourced from the company's idle self-owned funds [6]. Investment Method - In the third quarter of 2025, the company used 5.4 billion RMB to purchase government bond reverse repos, with investment periods of 7 days and 5 days [7][8]. Risk Analysis and Control Measures - The investment scope primarily includes high-security, liquid, and capital-preserving financial products, with risks associated with market fluctuations and macroeconomic changes [3][9]. - The company has established risk management protocols, including selecting qualified financial institutions and maintaining oversight of investment activities [10]. Impact on the Company - The use of idle funds for entrusted financial management is designed to not disrupt the company's daily operations or main business activities, aiming to improve fund efficiency and yield better investment returns [12].

证券代码：600998 证券简称：九州通 公告编号：临 2025- 070 九州通医药集团股份有限公司 关于 2025 年第三季度委托理财情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 九州通医药集团股份有限公司（以下简称"公司"）于 2024 年 12 月 8 日和 2025 年 1 月 6 日分别召开第六届董事会第十一次会议和 2025 年第一次 临时股东会，审议通过了《关于公司 2025 年度使用临时闲置资金委托理财预 计的议案》，同意公司使用不超过人民币 40 亿元（余额）的临时闲置流动资 金适时购买安全性高、流动性较好的理财产品，单个理财产品的投资期限不 超过 12 个月（一般不超过 3 个月）。 特别风险提示 公司委托理财的投资范围主要是安全性高、流动性好的保本型理财产品，主 要风险包括市场波动风险、宏观经济形势及货币政策、财政政策等宏观政策发生 变化带来的系统性风险等，委托理财的实际收益存在不确定性，敬请广大投资者 注意投资风险。 1 一、投资情况概述 （一）投资目的 基本情况 | 投 ...

截至2025年10月9日，楚昌投资持有公司股份362,525,962股（不含担保及信 托财产专户持有股份），持股比例为7.19%；"楚昌集团-国联民生保荐-22楚昌 EB01担保及信托财产专户"持有公司股份17,587,759股，持股比例为0.35%。本 次股票担保及信托登记解除后，上述担保及信托专户中的17,587,759股公司股份 将划转至楚昌投资证券账户，楚昌投资将持有公司股份380,113,721股（不含其他 两期可交换债券担保及信托财产专户持有股份），持股比例为7.54%；"楚昌集 1 团-国联民生保荐-22楚昌EB01担保及信托财产专户"将不再持有公司股份。本次 股票担保及信托登记解除后，公司控股股东及实际控制人不会发生变化，不构成 要约收购。 证券代码：600998 证券简称：九州通 公告编号：临 2025-069 九州通医药集团股份有限公司关于控股股东 完成2022年非公开发行可交换公司债券（第一期）兑付并 摘牌暨拟办理解除股票担保及信托登记的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2025 ...

Core Insights - The pharmaceutical commercial sector saw a slight increase of 0.17% on October 10, with Guofa Co., Ltd. leading the gains [1] - The Shanghai Composite Index closed at 3897.03, down 0.94%, while the Shenzhen Component Index closed at 13355.42, down 2.7% [1] Stock Performance - Guofa Co., Ltd. (600538) closed at 5.85, up 4.28% with a trading volume of 178,800 shares and a transaction value of 103 million yuan [1] - Other notable gainers included Dajia Weikang (301126) up 1.89%, Yingte Group (000411) up 1.77%, and Liuyao Group (603368) up 1.75% [1] - Conversely, the sector also experienced declines, with Saily Medical (603716) down 4.51% and Jianfa Zhixin (301584) down 4.01% [2] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 161 million yuan from institutional investors, while retail investors saw a net inflow of 214 million yuan [2] - The data indicates that while institutional investors were pulling back, retail investors were actively buying into the sector [2] Individual Stock Capital Flow - Shanghai Pharmaceuticals (601607) had a net inflow of 27.32 million yuan from institutional investors, while it faced a net outflow of 32.58 million yuan from speculative funds [3] - Dajia Weikang (301126) saw a net inflow of 4.95 million yuan from institutional investors, but also faced outflows from speculative funds [3] - Guofa Co., Ltd. (600538) had a net inflow of 4.07 million yuan from institutional investors, indicating some level of interest despite the overall outflow trend [3]

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 301015 | 百洋医药 | 27.17 | -2.96% | 5.74万 | 1.58亿 | | 301584 | C建发致 | 28.15 | -2.90% | 21.71万 | 6.15亿 | | 600833 | 第一医药 | 13.38 | -2.76% | 8.11万 | 260'T | | 301126 | 达嘉维康 | 11.13 | -2.37% | 4.04万 | 4537.69万 | | 603108 | 润达医疗 | 15.70 | -1.88% | 19.17万 | 3.00亿 | | 000705 | 浙江震元 | 9.78 | -1.41% | 13.46万 | 1.31亿 | | 002462 | 章章点 | 13.69 | -0.58% | 4.41万 | 6013.33万 | | 300937 | 药易购 | 26.53 | -0.49% | 1.29万 | 3415.25万 | | 600538 | 国发股份 ...

从资金流向上来看，当日医药商业板块主力资金净流入1486.86万元，游资资金净流出7521.88万元，散户 资金净流入6035.02万元。医药商业板块个股资金流向见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 301584 | C建发致 | 8225.62万 | 8.49% | -2828.35万 | -2.92% | -5397.28万 | -5.57% | | 600998 | 九州通 | 2389.11万 | 16.23% | -1071.49万 | -7.28% | -1317.63万 | -8.95% | | 600511 | 国药股份 | 895.78万 | 9.93% | -1003.50万 | -11.13% | 107.72万 | 1.19% | | 002589 | 瑞康医药 | 806.52万 | 19.20% | -436.26万 | -10.39% | -370.25万 | -8 ...

Core Insights - Hubei province is focusing on high-level opening up and enhancing its role as a market hub, with significant progress in trade and investment during the "14th Five-Year Plan" period [2][3][4] Trade and Economic Growth - Hubei's total retail sales increased from 1.8 trillion yuan in 2020 to 2.53 trillion yuan in 2024, with an average annual growth of 8.9% [3] - The province's import and export values have consistently crossed the thresholds of 500 billion, 600 billion, and 700 billion yuan from 2021 to 2024, achieving an average annual growth of 13.2% [3][4] - In the first eight months of 2025, Hubei's import and export growth reached 27.3%, the highest in Central China [3] Consumption and New Growth Drivers - The implementation of consumption upgrade policies has driven over 160 billion yuan in consumption, with significant growth in sectors like home appliances and new energy vehicles [3] - Online retail sales surged by 92.6% compared to the end of the "13th Five-Year Plan" [3] Foreign Trade and Market Expansion - Exports to countries involved in the Belt and Road Initiative increased by 131% compared to the end of the "13th Five-Year Plan," accounting for 53.3% of total exports [4] - The number of enterprises engaged in import and export activities rose to 9,570, with 14 enterprises exceeding 10 billion yuan in import and export value [4] Investment and Infrastructure Development - Hubei attracted 325 Fortune Global 500 companies, leading Central China in investment [5] - The province has established a comprehensive open platform system, including six comprehensive bonded zones and four bonded logistics centers [7] Logistics and Transportation - Hubei's logistics capabilities have been enhanced with the approval of the Huahu Airport as a comprehensive import port and the establishment of multiple international freight routes [7] - The province's highway network has surpassed 8,000 kilometers, achieving a significant milestone ahead of the "14th Five-Year Plan" targets [8]